港股異動 | 君實生物再漲超5%,公司稱仍在繼續新冠特效藥VV116兩項三期臨牀研究
$君實生物(01877.HK)$今日延續漲勢,截至發稿,漲5.47%,報42.4港元,成交額1.13億港元。
消息面上, 全球權威期刊《新英格蘭醫學雜誌》發表首箇中國自主研發的新冠創新藥臨牀試驗報告,稱君實生物旗下的新冠藥VV116的療效不遜於輝瑞口服藥Paxlovid。君實生物迴應新冠藥VV116進展稱,尚未提交上市申請,監管部門認爲還需要提供更多數據支持。
「這個項目對我們非常重要,我們肯定希望儘快提交審評。」君實生物高管迴應稱,「我們兩手都在做,一個是保持跟監管部門持續溝通,另一個是加快還在進行的兩項III期臨牀研究。」「VV116的應用場景非常廣闊,哪怕類比流感特效藥,每年也有一個穩定的收入,當然前提是要獲批。」
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.